Cognex Corp.

Cognex is a provider of machine vision products that capture and analyze visual information in order to automate tasks, primarily in manufacturing processes. Machine vision products are used to automate the manufacture and tracking of discrete items, such as mobile phones, aspirin bottles, and automobile tires, by locating, identifying, inspecting, and measuring them during the manufacturing or distribution process. The company provides a range of vision and ID products. The company's products range from vision sensors that are integrated, to PC-based systems for users. The company's products also have a variety of physical forms, depending upon the user's need.
  • TickerCGNX
  • ISINUS1924221039
  • ExchangeNASDAQ Stock Market
  • SectorElectronic & Electrical Equipment
  • CountryUnited States
Dave Nicoski ...
  • Ross LaDuke

Vermilion Compass: Weekly Equity Strategy

Round Trip Back To Resistance Our base case continues to be for near-term consolidation while the market determines the implications of states' reopening (i.e., the “wait-and-see” phase). Until this consolidation period resolves below support or above resistance we are maintaining a relatively neutral stance considering the wide range of outcomes. Below we highlight new developments which remain generally positive. Still, many major indexes are testing logical resistance and until we see breakouts it is hard to get too bullish. · Short-Term Levels. The S&P 500 is at the upper-end of ...

Dave Nicoski ...
  • Ross LaDuke

Vermilion Compass: Weekly Equity Strategy

S&P 500 Testing Key Resistance As we have outlined in recent weeks, our base case continues to be for near-term consolidation while the market is in a “wait-and-see” phase as it relates to states re-opening. The S&P 500 is again testing key resistance at the 61.8% Fibonacci retracement level of 2934.49 and also the 2950-3000 level we previously identified. We continue to have concerns that lead us to believe the market is not yet out of the woods, however these concerns are counterbalanced by a number of positive developments. When it comes down to it, key support levels mentioned last week i...

Dave Nicoski ...
  • Ross LaDuke

Vital Signs: Actionable charts

Key Points: • Many Consumer Discretionary names are staging reversals or developing bullish bases. (ex. CPRI, CRI, OXM, PENN, LOCO, PZZA, DPZ, WW, CHS, ZUMZ, and GES) • The Healthcare Sector has a significant number of names reversing downtrend, breaking out of bases, and in uptrends (ex. CAH, TCMD, THC, SEM, MGLN, RGEN, REGN, MEDP, PRAH, and BMY) • Semis and Semi suppliers continue to develop positively. (ex. UCTT, ICHR, FORM, AEIS, and BRKS)

Dave Nicoski ...
  • Ross LaDuke

Vermilion Compass: Weekly Equity Strategy

Round Trip Back To Resistance Our base case continues to be for near-term consolidation while the market determines the implications of states' reopening (i.e., the “wait-and-see” phase). Until this consolidation period resolves below support or above resistance we are maintaining a relatively neutral stance considering the wide range of outcomes. Below we highlight new developments which remain generally positive. Still, many major indexes are testing logical resistance and until we see breakouts it is hard to get too bullish. · Short-Term Levels. The S&P 500 is at the upper-end of ...

Dave Nicoski ...
  • Ross LaDuke

Vermilion Compass: Weekly Equity Strategy

S&P 500 Testing Key Resistance As we have outlined in recent weeks, our base case continues to be for near-term consolidation while the market is in a “wait-and-see” phase as it relates to states re-opening. The S&P 500 is again testing key resistance at the 61.8% Fibonacci retracement level of 2934.49 and also the 2950-3000 level we previously identified. We continue to have concerns that lead us to believe the market is not yet out of the woods, however these concerns are counterbalanced by a number of positive developments. When it comes down to it, key support levels mentioned last week i...

Feasibility Study Results in December to be a Catalyst for this Junior

Feasibility Study Results in December to be a Catalyst for this Junior